CRISPR Therapeutics AGCRISPR Therapeutics AG - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Comprehensive Sustainability assessment of CRISPR Therapeutics AG are reached by logging in. The analysis of CRISPR Therapeutics AG leverages data from across the web as well as from public filings by CRISPR Therapeutics AG. Alternative corporations in the scoring industry group for CRISPR Therapeutics AG are displayed below.

CRISPR Therapeutics AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 2.3, social score of 2.3 and governance score of 5.7.

SDG Transparency Score for CRISPR Therapeutics AG 

3.5

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for CRISPR Therapeutics AG 
2.3

Environmental

2.3

Social

5.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
.........
1575Vitality Biopharma Inc
3.6
Medium
1575Zhejiang East Asia Pharmaceutical Co Ltd
3.6
Medium
1617CRISPR Therapeutics AG
3.5
Medium
1617Anika Therapeutics Inc
3.5
Medium
1617Aerovate Therapeutics Inc
3.5
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does CRISPR Therapeutics AG have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose current and historical energy intensity?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG report the average age of the workforce?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose cybersecurity risks?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG offer flexible work?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG conduct supply chain audits?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does CRISPR Therapeutics AG conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose water use targets?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did CRISPR Therapeutics AG have a product recall in the last two years?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose incidents of discrimination?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has CRISPR Therapeutics AG issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose parental leave metrics?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is CRISPR Therapeutics AG involved in embryonic stem cell research?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose its waste policy?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG report according to TCFD requirements?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose energy use targets?

LockedSign up for free to unlock

Does CRISPR Therapeutics AG disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does CRISPR Therapeutics AG have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for CRISPR Therapeutics AG
These potential risks are based on the size, segment and geographies of the company.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Sorry!

Failed to process!